Navigation Links
AANMA Announces Launch of Free Web-Based Education Program for Patients Transitioning From CFC to HFA Inhalers
Date:12/3/2008

FAIRFAX, Va., Dec. 3 /PRNewswire-USNewswire/ -- Allergy & Asthma Network Mothers of Asthmatics (AANMA) announced today that a new Web-based video geared to help people successfully manage the transition from CFC albuterol inhalers to HFA inhalers is now available at its Web site, www.breatherville.org. Smart Moves to an HFA Inhaler uses technology that allows viewers to ask questions in everyday language and immediately receive a response with relevant, highly focused answers. Users can obtain valuable information about why inhalers are changing, the differences between newer and older inhalers, cost concerns and how to use new HFA inhalers.

"We created this video to help patients and their families learn more about this federal mandate, as a significant number of patients are still not aware of how to safely go about making this change," said Nancy Sander, president and founder of AANMA. "At the end of the year, inhalers are changing. These changes are mandatory, and there are important decisions to make about treatment options that require thoughtful consideration of the patient's medical history and current respiratory health status."

In less than 30 days, life-saving albuterol inhalers used by nearly 40 million patients with respiratory disorders will no longer be sold. After December 31, 2008, it will no longer be permissible to manufacture or sell albuterol inhalers in the United States that contain chlorofluorocarbon (CFC) propellants, because they destroy the Earth's ozone layer. These inhalers have been replaced with four distinct non-CFC propelled alternatives, which contain hydrofluoroalkane (HFA) propellant.

While the transition has been forthcoming for some time, data from IMS Health show that an estimated 14 million CFC prescriptions have yet to be transitioned to HFA MDIs.(1) The absence of a medically responsible transition protocol leaves patients unknowingly exposed to health risks beyond their control.

Patients with asthma, COPD and other respiratory conditions use albuterol at the first sign of symptoms, before exercise and when experiencing breathing exacerbations. Because there are significant differences between CFC and HFA inhalers, patients and medical professionals need to have the opportunity to make the switch in a medically responsible way.

The Web module is hosted by former CNN Medical correspondent Rea Blakey, and supported by an educational grant from Sepracor.

For more information about the MDI transition, please visit AANMA's MDI Transition Web page at www.mditransition.org. Patients seeking information can also call AANMA's Patient Support Center at 800-315-8056.

About AANMA

Founded in 1985, Allergy & Asthma Network Mothers of Asthmatics is the leading national nonprofit family organization dedicated to eliminating suffering and death due to asthma, allergies and related conditions. AANMA's core areas of expertise are education, advocacy and outreach. Call 800.878.4403 or visit www.breatherville.org.

(1) IMS NPA, August 22, 2008


'/>"/>
SOURCE Allergy & Asthma Network Mothers of Asthmatics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lucas Group Announces Their Executive Recruitment Military Hiring Conference Schedule for December 2008
2. Axiom Consulting Partners Announces the Results of its Return On Sales Investment Survey
3. United American Healthcare Corporation Announces Stock Repurchase Program
4. eOn Communications Announces GSA Contract
5. Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
6. USHIFU Announces First Sonablate(R) HIFU Device in India for Minimally Invasive Prostate Cancer Treatment
7. Elsevier announces the 2008 supplement of Reproductive Health Matters
8. Pascal Metrics Announces Patient Safety Culture Services Offering
9. Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology
10. Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial
11. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Francisco, CA (PRWEB) , ... February 27, 2017 ... ... center for hair transplantation therapy, is proud to announce a new informational post ... hair therapy procedures. Follicular Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation ...
(Date:2/26/2017)... (PRWEB) , ... February 25, 2017 , ... The February ... Jong-un, heightened awareness and concern over nerve agents and the deadly use of chemical ... human nervous system and how even small doses can be lethal. , Jay Jagannathan, ...
(Date:2/26/2017)... ... February 26, 2017 , ... NuevaCare, a leading home care agency based ... and Palo Alto, is proud to announce an important upgrade to its geographic information ... home care close to home, and by having city-specific pages, NuevaCare is answering that ...
(Date:2/26/2017)... KS (PRWEB) , ... February ... ... StaffBridge sets a new technology standard in staffing, scheduling, and reporting for ... monitor, and predict activity throughout the entire staffing process. StaffBridge technology improves ...
(Date:2/26/2017)... ... 2017 , ... Occupational pesticide exposure is linked to an ... according to a study released today at the 1st Pan American Parkinson’s and ... pesticides and incidence of sporadic PD through occupational exposure. This latest study, led ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Australien, 24. Februar 2017 ITL Limited, ... des Gesundheitsbereiches, ist erfreut, für das zum 31. ... entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. Eine ... zum Wachstum" finden Sie hier . ... nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... -- This report analyzes the worldwide markets for Chiral Technology ... Products: Intermediates, Analytical, and Others. The End Use markets ... The report provides separate comprehensive analytics for the US, ... , and Rest of World. Annual estimates and forecasts ... a six-year historic analysis is provided for these markets. ...
(Date:2/24/2017)... Feb 24, 2017 Medivir AB ... for a new Board of Directors that will be ... Nomination Committee comprises representatives of the company,s three largest ... 2016 who have accepted a seat on the Nomination ... of the 2016-2017 Nomination Committee was as follows:  ...
Breaking Medicine Technology: